Neurocrine Biosciences | NBIX - Capital De Empréstimo





Capital De Empréstimo Alterar Data
AbbVie USD 62.97B 12M 2025-09
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
ALKERMES USD 285.82M 639K 2024-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Amgen USD 50B 2.43B 2025-12
Biogen USD 6.29B 1.4M 2025-09
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Cytokinetics USD 1.12B 957.23M 2025-12
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 22.14B 5M 2025-09
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Incyte USD 30.2M 5.17M 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
Nektar Therapeutics USD 107.51M 10.35M 2024-06
Neurocrine Biosciences USD 169.5M 500K 2023-03
Pfizer USD 57.41B 93M 2025-09
Prothena USD 0 0 2024-12
Regeneron Pharmaceuticals USD 2.71B 720.4M 2025-12
Repligen USD 542.21M 4.29M 2025-12
Rigel Pharmaceuticals USD 0 0 2024-09
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Teva Pharmaceutical Industries USD 14.99B 1.78B 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03
Xoma USD 94.38M 7.82M 2025-09